These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 15608077

  • 21. CEP-26401 (irdabisant), a potent and selective histamine H₃ receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.
    Raddatz R, Hudkins RL, Mathiasen JR, Gruner JA, Flood DG, Aimone LD, Le S, Schaffhauser H, Duzic E, Gasior M, Bozyczko-Coyne D, Marino MJ, Ator MA, Bacon ER, Mallamo JP, Williams M.
    J Pharmacol Exp Ther; 2012 Jan; 340(1):124-33. PubMed ID: 22001260
    [Abstract] [Full Text] [Related]

  • 22. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL, Phillips JG, Gregory R, Pawlowski GP, Fadnis L, Khan MA, Ali SM, Tedford CE.
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [Abstract] [Full Text] [Related]

  • 23. Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
    Zhang M, Ballard ME, Pan L, Roberts S, Faghih R, Cowart M, Esbenshade TA, Fox GB, Decker MW, Hancock AA, Rueter LE.
    Brain Res; 2005 May 31; 1045(1-2):142-9. PubMed ID: 15910772
    [Abstract] [Full Text] [Related]

  • 24. SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodents.
    Griebel G, Pichat P, Pruniaux MP, Beeské S, Lopez-Grancha M, Genet E, Terranova JP, Castro A, Sánchez JA, Black M, Varty GB, Weiner I, Arad M, Barak S, De Levie A, Guillot E.
    Pharmacol Biochem Behav; 2012 Aug 31; 102(2):203-14. PubMed ID: 22542742
    [Abstract] [Full Text] [Related]

  • 25. Effects of the histamine H3 receptor antagonist ABT-239 on acute and repeated nicotine locomotor responses in rats.
    Miszkiel J, Kruk M, McCreary AC, Przegaliński E, Biała G, Filip M.
    Pharmacol Rep; 2011 Aug 31; 63(6):1553-9. PubMed ID: 22358104
    [Abstract] [Full Text] [Related]

  • 26. Influence of a selective histamine H3 receptor antagonist on hypothalamic neural activity, food intake and body weight.
    Malmlöf K, Zaragoza F, Golozoubova V, Refsgaard HH, Cremers T, Raun K, Wulff BS, Johansen PB, Westerink B, Rimvall K.
    Int J Obes (Lond); 2005 Dec 31; 29(12):1402-12. PubMed ID: 16151415
    [Abstract] [Full Text] [Related]

  • 27. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.
    Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA, Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N.
    Eur J Pharmacol; 2006 Dec 28; 553(1-3):109-19. PubMed ID: 17069795
    [Abstract] [Full Text] [Related]

  • 28. Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.
    Southam E, Cilia J, Gartlon JE, Woolley ML, Lacroix LP, Jennings CA, Cluderay JE, Reavill C, Rourke C, Wilson DM, Dawson LA, Medhurst AD, Jones DN.
    Psychopharmacology (Berl); 2009 Jan 28; 201(4):483-94. PubMed ID: 18762914
    [Abstract] [Full Text] [Related]

  • 29. BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology.
    Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, Lecomte JM, Parmentier R, Anaclet C, Lin JS, Bertaina-Anglade V, la Rochelle CD, d'Aniello F, Rouleau A, Gbahou F, Arrang JM, Ganellin CR, Stark H, Schunack W, Schwartz JC.
    J Pharmacol Exp Ther; 2007 Jan 28; 320(1):365-75. PubMed ID: 17005916
    [Abstract] [Full Text] [Related]

  • 30. Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice.
    Nuutinen S, Vanhanen J, Pigni MC, Panula P.
    Neuropharmacology; 2011 Jun 28; 60(7-8):1193-9. PubMed ID: 21044640
    [Abstract] [Full Text] [Related]

  • 31. In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.
    Bitner RS, Markosyan S, Nikkel AL, Brioni JD.
    Neuropharmacology; 2011 Jun 28; 60(2-3):460-6. PubMed ID: 21044639
    [Abstract] [Full Text] [Related]

  • 32. H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization.
    Komater VA, Browman KE, Curzon P, Hancock AA, Decker MW, Fox GB.
    Psychopharmacology (Berl); 2003 Jun 28; 167(4):363-72. PubMed ID: 12682709
    [Abstract] [Full Text] [Related]

  • 33. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
    Grimwood S, Lu Y, Schmidt AW, Vanase-Frawley MA, Sawant-Basak A, Miller E, McLean S, Freeman J, Wong S, McLaughlin JP, Verhoest PR.
    J Pharmacol Exp Ther; 2011 Nov 28; 339(2):555-66. PubMed ID: 21821697
    [Abstract] [Full Text] [Related]

  • 34. Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist.
    Hancock AA, Bennani YL, Bush EN, Esbenshade TA, Faghih R, Fox GB, Jacobson P, Knourek-Segel V, Krueger KM, Nuss ME, Pan JB, Shapiro R, Witte DG, Yao BB.
    Eur J Pharmacol; 2004 Mar 08; 487(1-3):183-97. PubMed ID: 15033391
    [Abstract] [Full Text] [Related]

  • 35. Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse.
    Provensi G, Costa A, Passani MB, Blandina P.
    Neuropharmacology; 2016 Oct 08; 109():139-147. PubMed ID: 27291828
    [Abstract] [Full Text] [Related]

  • 36. Evidence for tolerance following repeated dosing in rats with ciproxifan, but not with A-304121.
    Pan JB, Yao BB, Miller TR, Kroeger PE, Bennani YL, Komater VA, Esbenshade TA, Hancock AA, Decker MW, Fox GB.
    Life Sci; 2006 Aug 29; 79(14):1366-79. PubMed ID: 16730751
    [Abstract] [Full Text] [Related]

  • 37. Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer's disease.
    Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD.
    J Pharmacol Exp Ther; 2011 Jan 29; 336(1):38-46. PubMed ID: 20864505
    [Abstract] [Full Text] [Related]

  • 38. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ.
    J Pharmacol Exp Ther; 2009 Nov 29; 331(2):574-90. PubMed ID: 19661377
    [Abstract] [Full Text] [Related]

  • 39. Effects of the cognition-enhancing agent ABT-239 on fetal ethanol-induced deficits in dentate gyrus synaptic plasticity.
    Varaschin RK, Akers KG, Rosenberg MJ, Hamilton DA, Savage DD.
    J Pharmacol Exp Ther; 2010 Jul 29; 334(1):191-8. PubMed ID: 20308329
    [Abstract] [Full Text] [Related]

  • 40. Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia.
    Brown JW, Whitehead CA, Basso AM, Rueter LE, Zhang M.
    Int J Neuropsychopharmacol; 2013 May 29; 16(4):889-904. PubMed ID: 22906530
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.